REGENXBIO Inc. (NASDAQ:RGNX) Shares Bought by Hennion & Walsh Asset Management Inc.

Hennion & Walsh Asset Management Inc. boosted its stake in shares of REGENXBIO Inc. (NASDAQ:RGNX) by 44.2% in the first quarter, according to its most recent disclosure with the SEC. The firm owned 106,284 shares of the biotechnology company’s stock after acquiring an additional 32,584 shares during the period. Hennion & Walsh Asset Management Inc. owned about 0.22% of REGENXBIO worth $2,239,000 at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in the stock. Napatree Capital LLC acquired a new position in REGENXBIO during the fourth quarter worth $720,000. PNC Financial Services Group Inc. grew its holdings in shares of REGENXBIO by 73.5% during the fourth quarter. PNC Financial Services Group Inc. now owns 1,761 shares of the biotechnology company’s stock worth $32,000 after buying an additional 746 shares in the last quarter. Virtu Financial LLC purchased a new stake in shares of REGENXBIO during the fourth quarter worth $377,000. Perceptive Advisors LLC purchased a new stake in shares of REGENXBIO during the fourth quarter worth $6,146,000. Finally, Panagora Asset Management Inc. grew its holdings in shares of REGENXBIO by 2.4% during the fourth quarter. Panagora Asset Management Inc. now owns 222,363 shares of the biotechnology company’s stock worth $3,991,000 after buying an additional 5,184 shares in the last quarter. 88.08% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

RGNX has been the subject of a number of research reports. Stifel Nicolaus reaffirmed a “buy” rating and set a $40.00 target price on shares of REGENXBIO in a report on Friday, April 12th. The Goldman Sachs Group initiated coverage on shares of REGENXBIO in a report on Friday, June 7th. They set a “buy” rating and a $38.00 target price for the company. StockNews.com raised shares of REGENXBIO from a “sell” rating to a “hold” rating in a report on Tuesday, June 18th. Royal Bank of Canada raised shares of REGENXBIO from a “sector perform” rating to an “outperform” rating and upped their price objective for the company from $20.00 to $35.00 in a report on Friday, March 8th. Finally, Leerink Partnrs raised shares of REGENXBIO from a “market perform” rating to an “outperform” rating in a report on Wednesday, March 6th. Three analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $38.58.

Insider Transactions at REGENXBIO

In other news, CEO Kenneth T. Mills sold 15,000 shares of the stock in a transaction dated Tuesday, May 14th. The shares were sold at an average price of $15.81, for a total transaction of $237,150.00. Following the sale, the chief executive officer now owns 408,035 shares of the company’s stock, valued at $6,451,033.35. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 13.13% of the company’s stock.

REGENXBIO Trading Up 0.6 %

RGNX stock traded up $0.07 during mid-day trading on Friday, hitting $11.70. 1,563,503 shares of the company were exchanged, compared to its average volume of 661,268. The business has a fifty day simple moving average of $14.58 and a 200-day simple moving average of $16.90. REGENXBIO Inc. has a 12-month low of $11.33 and a 12-month high of $28.80.

REGENXBIO (NASDAQ:RGNX) last announced its earnings results on Wednesday, May 8th. The biotechnology company reported ($1.38) earnings per share for the quarter, missing the consensus estimate of ($1.28) by ($0.10). The company had revenue of $15.60 million for the quarter, compared to analysts’ expectations of $23.52 million. REGENXBIO had a negative return on equity of 70.72% and a negative net margin of 299.96%. The company’s quarterly revenue was down 18.3% compared to the same quarter last year. During the same period last year, the business earned ($1.53) EPS. On average, analysts predict that REGENXBIO Inc. will post -4.37 EPS for the current year.

About REGENXBIO

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.